Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients.

Hamostaseologie - 1 Jun 2026

Morath Olga, Crodel Carl, Rinke Jenny, Sander Inken, Tekbas Aysun, Meggendorfer Manja, Baer Constance, Hochhaus Andreas, Ernst Thomas

Abstract excerpt

Background: The risk of thrombosis and bleeding in myelofibrosis (MF) has been historically underappreciated. We sought to investigate potential molecular and clinical risk factors for venous (VTE) and arterial (ATE) thrombotic events as well as bleeding episodes. Methods: Data from 246 consecutive MF patients were analyzed. Driver mutations were tested in 191 patients. Results: In total, 181 mutations were found...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Comorbidity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemorrhage

Share to Janus Kinase 2

Share to Prevalence

Share to Primary Myelofibrosis

Share to Receptors, Thrombopoietin

Share to Thrombosis

Source

Identifiers

PMID: 39708833
DOI: 10.1055/a-2410-8530

Genes

JAK2
MPL
CALR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients.PMID 39708833Read ↗

Thrombotic incidents in patients with myelofibrosis suggest to be independent of JAK2 V617f mutational status.Semantic proximity Read ↗

Thrombosis in primary myelofibrosis: incidence and risk factors.Semantic proximity Read ↗

Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision OncologySemantic proximity Read ↗

[Analysis of risk factors for thromboembolism in patients with JAK2V617F gene mutation positive myeloproliferative neoplasms].Semantic proximity Read ↗

Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectivesSemantic proximity Read ↗

JAK2 mutation-related disease and thrombosis.Semantic proximity Read ↗

Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.Semantic proximity Read ↗

Comparison of JAK2V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.Semantic proximity Read ↗

The new WHO classification for essential thrombocythemia calls for revision of available evidences.Semantic proximity Read ↗

Molecular biomarkers of thrombosis in myeloproliferative neoplasms.Semantic proximity Read ↗

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.Semantic proximity Read ↗

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS scoreSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.